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Circulating tumor cells (CTCs) are en-
riched for the precursors of metastasis,
but their composition has not been fully
defined. Ting et al. have utilized a micro-
fluidic device to perform single-cell RNA
sequencing of pancreatic CTCs, identi-
fying three distinct populations that sug-
gest multiple paths in the metastatic
cascade. Extracellular matrix gene
expression in particular was highly en-
riched in CTCs, pointing to a contribution
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Circulating tumor cells (CTCs) are shed from primary
tumors into the bloodstream, mediating the hema-
togenous spread of cancer to distant organs. To
define their composition, we compared genome-
wide expression profiles of CTCs with matched pri-
mary tumors in a mouse model of pancreatic cancer,
isolating individual CTCs using epitope-independent
microfluidic capture, followed by single-cell RNA
sequencing. CTCs clustered separately from primary
tumors and tumor-derived cell lines, showing low-
proliferative signatures, enrichment for the stem-
cell-associated gene Aldh1a2, biphenotypic expres-
sion of epithelial and mesenchymal markers, and
expression of Igfbp5, a gene transcript enriched at
the epithelial-stromal interface. Mouse as well as
human pancreatic CTCs exhibit a very high expres-
sion of stromal-derived extracellular matrix (ECM)
proteins, including SPARC, whose knockdown in
cancer cells suppresses cell migration and invasive-
ness. The aberrant expression by CTCs of stromal
ECM genes points to their contribution of microenvi-
ronmental signals for the spread of cancer to distant
organs.INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal
cancer, which stems from the rapid dissemination of tumor
cells leading to widespread metastasis. While local tissue andCell Relymphatic invasion are evident even in early PDAC, the presence
of circulating tumor cells (CTCs) in the bloodstream ultimately
leads to spread of cancer to distant organs. CTCs are rare, esti-
mated at one to ten tumor cells among ten billion normal blood
cells in a milliliter of blood. As such, their isolation and molecular
analysis has posed a significant technological challenge (Pantel
et al., 2008; Yu et al., 2011). Given their role in blood-borne
metastasis, CTC populations are likely to be enriched for meta-
static precursors, and their analysis may identify potential thera-
peutic targets as well as provide opportunities for early detection
of pancreatic cancer.
Genetically engineered mouse pancreatic cancer models
have provided important insight into the progression of this dis-
ease. Specifically, the genetically engineered LSL-KrasG12D,
Trp53flox/flox or +, Pdx1-Cre (KPC) mouse model recapitulates
the histological progression from preneoplastic pancreatic intra-
epithelial neoplasia to invasive carcinoma (Bardeesy et al.,
2006). Recent studies have suggested that epithelial-to-mesen-
chymal transition (EMT) occurs early in this model, potentially
enhancing tumor invasiveness (Rhim et al., 2012). In an initial mo-
lecular characterization of mouse pancreatic CTCs, we under-
took RNA sequencing (RNA-seq) of CTC-enriched populations,
identifying activation of noncanonical WNT signaling as a recur-
rent event, potentially contributing to the anoikis resistance
of circulating epithelial cells (Yu et al., 2012). In that study, anal-
ysis of pooled CTCs, enriched from the blood but still contami-
nated with leukocytes, was accomplished using single-molecule
RNA sequencing, combined with digital subtraction of matched
leukocyte RNA reads, so as to derive a CTC-specific expression
signature. However, transcriptome analysis of such partially pu-
rified cell populations is limited by depth of coverage to the most
highly differentially expressed genes, and such studies of bulk
CTC populations cannot resolve the degree of heterogeneity
across these poorly understood cell populations.ports 8, 1905–1918, September 25, 2014 ª2014 The Authors 1905
Figure 1. CTC Single-Cell Isolation
(A) Schematic of the CTC-iChip-negative inertial
focusing device system.
(B) Mouse WBC depletion consistency between
normal and cancer mouse models. WBC depletion
is shown in log10.
(C) CTC enumeration by immunofluorescent
staining (CK+/CD45-/DAPI+) from normal and
cancer mice. Bar represents mean.
(D) Representative image of CK-positive CTCs.
DAPI (blue), CK (red), and CD45 (green). Scale bar,
20 mm. Bright-field image highlighting lack of im-
munomagnetic anti-CD45 beads on CK+ CTCs
(white circle).To achieve deep RNA-sequencing profiles of CTCs at the
single-cell level, we applied an inertial focusing-enhancedmicro-
fluidic device, the CTC-iChip, which allows high-efficiency nega-
tive depletion of normal blood cells, leaving CTCs in solution
where they can be individually selected and analyzed as single
cells (Ozkumur et al., 2013). This antigen-agnostic isolation of
CTCs enables the characterization of CTCs with both epithelial
and mesenchymal characteristics. Further, the high quality of
RNA purified from viable, untagged CTCs is particularly well
suited for detailed transcriptome analysis. We applied the
CTC-iChip to the pancreatic cancer mouse model that allows
for simultaneous analysis of primary tumor and CTCs, with the
shared driver mutations across different animals facilitating the
identification of CTC-specific heterogeneity. Here, we present
a comprehensive transcriptome analysis of CTCs at the single-
cell level, pointing to distinct cell subsets within CTC popula-
tions. Notably, we have identified the unexpected abundant
expression of extracellular matrix (ECM) genes in mouse pancre-
atic CTCs and across human CTCs of pancreatic, breast, and
prostate origin. Consistent with the importance of tumor
stroma-derived ECM signaling in targeting cancer cell metas-
tasis (Zhang et al., 2013), the cell-autonomous expression of1906 Cell Reports 8, 1905–1918, September 25, 2014 ª2014 The AuthorsECM genes by CTCs may contribute to
the dissemination of cancer to distal
organs.
RESULTS
Isolation of Mouse Pancreatic CTCs
The CTC-iChip combines initial hydrody-
namic size-based separation of all nucle-
ated cells (leukocytes [WBCs] and CTCs)
away from red blood cells, platelets,
and plasma, with subsequent inertial
focusing of the nucleated cells into a sin-
gle streamline to achieve high-efficiency
in-line magnetic sorting. While tumor
epitopes are highly variable, WBC cell-
surface markers are well established;
applying magnetic-conjugated anti-WBC
to this very high-throughput microfluidic
cell-separation device can thus exclude
the vast majority of WBCs to reveal asmall number of untagged CTCs (Figure 1A). Whole-blood label-
ing using 100 anti-CD45 beads per WBC achieved >103 deple-
tion in normal mice, mice bearing orthotopic tumors, and the
KPC mice (Figure 1B).
We first tested the efficacy of the CTC-iChip using a GFP-
tagged mouse PDAC cell line (NB508). CTC recovery through
the CTC-iChip was measured to be 95% (mean ± 3% SD), us-
ing GFP-tagged NB508 cells spiked into whole mouse blood.
Applying the CTC-iChip to orthotopic tumors derived from
pancreatic inoculation of GFP-tagged NB508 cells generated
>1,000 CTCs/ml in all three mice tested (Figure 1C). Finally,
CTC analysis of blood specimens from KPC mice bearing
endogenous tumors, using dual immunofluorescent staining
of cells with the epithelial marker pan-cytokeratin (CK) and
the leukocyte marker CD45, revealed a median 118 CTCs/ml
(mean 429 CTCs/ml; range, 0–1,694) (Figures 1C and 1D). No
CK-positive cells were detected in seven healthy control
mice. The majority of CD45-positive cells that remained in
the product after blood processing through the microfluidic de-
vice retained immunomagnetic beads on their surface. Thus,
the untagged cells constituting CTCs were readily distin-
guished from WBCs in the final CTC-iChip product (Figure 1D),
enabling single-cell manipulation without additional surface
epitope staining.
Single-CTC RNA-Seq
Five tumor-bearing KPC mice generated a total of 168 single
CTCs (Figure S1) that were subjected to a modified single-cell
amplification and library protocol (Tang et al., 2010), followed
by a screen for RNA quality (Gapdh, Actb). Of these, 75
(45%) were of sufficient quality to proceed to further amplifica-
tion and library construction for next-generation sequencing. It
is noteworthy that a majority of candidate CTCs (55%) ap-
peared morphologically intact but had degraded RNA. These
cells likely represent tumor cells that have lost viability in the
bloodstream. Given the rapid processing of blood samples
from mouse models, the minimal shear condition in the micro-
fluidic device, and the preserved RNA quality of control cells
processed identically, it is unlikely that cells underwent such
damage during in vitro purification. For comparison, single-
cell RNA-seq was also performed on 12 WBCs from a control
mouse, 12 mouse embryonic fibroblasts (MEFs), and 16 single
cells from the mouse NB508 pancreatic cancer cell line. Over
90% of single cells from NB508 and MEF cultures met criteria
for sequencing quality, highlighting the high frequency of
CTCs with compromised RNA templates under the same con-
ditions. To compare CTC profiles to that of matched parental
tumors harvested at the time of CTC isolation, bulk RNA from
each primary tumor was diluted to 1 or 10 cell equivalents (10
or 100 pg RNA) and subjected to the same amplification and
RNA-seq protocol (n = 34; minimum of eight replicates from
four matched tumors).
Single-cell RNA-seq performance was comparable for all
samples analyzed, with a mean 4.4–8.5 million reads, of which
a mean 46%–61% uniquely aligned to the mouse genome (Fig-
ure S1). Genome-aligned reads were annotated and counted us-
ing UCSC Known Gene transcriptome reference and normalized
in reads per million (rpm). Normalized reads were then analyzed
by unsupervised hierarchical clustering (Figure 2A). Single-cell
transcriptomes from MEFs, the NB508 pancreatic cancer cell
line, and normal WBCs clustered tightly, supporting the analytic
reliability of the RNA-seq strategy. Three distinct clustering
patterns of candidate CTCs were identified, all of which were
distinct from matched primary tumor sequences and cancer
cell lines. Principal component analysis shows the clustering
and interrelationships of these different groups (Figure 2B).
The uniform genetic drivers in the KPC mouse model made it
possible to quantify the degree of cellular heterogeneity in
CTCs derived from individual mice and across different mice.
Single-cell heterogeneity within each CTC cluster was assessed
by intracluster correlation coefficients, where lower correlation
coefficients reflect higher heterogeneity (Figure S1). As ex-
pected, CTC clusters showed considerably more heterogeneity
(mean 0.42, 95% confidence interval [CI] 0.36–0.47) than single
cells derived from the NB508 cancer cell line (mean 0.86, 95%
CI 0.80-0.91, p value 1.2 3 1015). To assess heterogeneity of
cells within a primary PDAC, a conditional Tomato/enhanced
EGFP (EGFP) (mT/mG) expression marker (Muzumdar et al.,
2007) was crossed with the KPC mouse to generate a lineage-
tagged mouse tumor (KPC-mT/mG) and was used to isolateCell Reindividual EGFP-positive primary tumor cells away from contam-
inating stromal cells. A primary tumor (TuGMP3) was disaggre-
gated into single-cell suspension, and 20 EGFP-positive
cells were subjected to RNA-seq. The single primary tumor cells
clustered with the previously analyzed bulk tumor material (Fig-
ure S2), with a heterogeneity score (mean 0.38, 95% CI 0.28–
0.47) similar to that of CTCs (p value 0.49).
In summary, we achieved single-cell RNA-seq of mouse
pancreatic CTCs isolated without positive selection bias, along
with parental tumors, an established genotype-matched cancer
cell line, MEFs, and WBCs. CTCs clustered separately from the
primary tumor (both bulk tumor and isolated single cells) and
from the tumor-derived cell line, with comparable degrees of
intercellular heterogeneity between CTCs and primary tumor
cells.
Defining Subsets of Pancreatic CTCs
To identify and classify candidate CTCs, we initially applied gene
sets for known epithelial, hematopoietic, and endothelial
markers across all clustered samples. As expected, epithelial
markers (Krt7,Krt8,Krt18,Krt19, Epcam, Egfr,Cdh1) were highly
expressed in primary pancreatic tumors and in the cancer cell
line NB508 and nearly absent in the nonepithelial MEFs and in
normal WBCs (Figure S3). In contrast, hematopoietic markers
(Ptprc/Cd45, Csf3r/Cd114, Cd14, Fcgr3/Cd16, Itga2b/Cd41,
Itgb3/Cd61) were present in normal WBCs and absent in
NB508 and MEFs. Some expression of hematopoietic markers
was detectable in the bulk primary tumor samples, consistent
with varying degrees of leukocytic infiltrates. No specific cluster
of endothelial cells was identified, based on expression of char-
acteristic markers (Cdh5/Cd144, Vwf, Thbd/Cd141, Pecam1/
Cd31, Mcam/Cd146, Sele/E-selectin, Cd34) and absence of
epithelial and hematopoietic markers.
Interrogation of single cells isolated by CD45 depletion from
tumor-bearing mice, using the epithelial, hematopoietic, and
endothelial markers, revealed notable differences among the
three major candidate CTC groupings (clusters 1, 3, and 7; Fig-
ures 3A and S3). Cluster 3 showed strong expression of epithelial
markers, consistent with a ‘‘classical’’ CTC phenotype (denoted
CTC-c). A subset of these cells expressed Cd34, an endothelial
progenitor marker that is also found in mesenchymal cells
including MEFs (Figures 3A and S3) and stromal cells (Krause
et al., 1994), but other characteristic endothelial lineage markers
were absent. Clusters 1 and 7 were more complex, with the
former noteworthy for enrichment of platelet markers CD41
(Itga2b) and CD61 (Itgb3) (hence denoted CTC-plt) and the latter
having a prominent cellular proliferation signature (CTC-pro).
To better define the characteristics of each candidate CTC
cluster, we used a nonparametric differential gene expression
analysis including a rank product (RP) methodology adapted
to variations in absolute transcript levels and differences in tran-
scriptome representation from cell to cell (Breitling et al., 2004).
Setting highly stringent parameters (false discovery rate% 0.01),
the control comparison of primary tumors versus WBCs identi-
fied 927 genes relatively overexpressed in tumors and 293 genes
high in WBCs, including the expected differential expression of
epithelial tumor markers keratin 7, 8, 18, and 19, versus the
leukocyte-specific CD45 (Table S1). Comparing the classicalports 8, 1905–1918, September 25, 2014 ª2014 The Authors 1907
Figure 2. Single-Cell RNA-Seq Global Analysis
(A) Unsupervised hierarchical clustering of candidate single CTCs (1, 3, and 7), singleWBCs (2), singleMEFs (5), single NB508 cancer cell line (6), and bulk primary
tumors diluted to 10 or 100 pg of RNA (4). CTC-c, classical CTCs; CTC-plt, platelet-adhered CTCs; CTC-pro, proliferative CTCs. Data shown log transformed and
median polished.
(B) Principal component analysis of single-cell samples.CTC cluster to WBCs also showed enrichment for cytokeratin 18
and 19 in CTC-c versus CD45 in WBCs, validating the RP meth-
odology to identify relevant differentially expressed genes be-
tween single-cell populations.1908 Cell Reports 8, 1905–1918, September 25, 2014 ª2014 The AuThe most abundant CTC cluster, CTC-c, comprised 41 of 75
cells (55%) meeting established criteria for epithelial tumor cells
(versus CTC-plt: 32%; CTC-pro: 13%). Compared with matched
primary tumors, CTCs had 878 transcripts increased inthors
Figure 3. Targeted Analysis of Single-Cell RNA-Seq Data
(A) Expression heatmap of epithelial, hematopoietic, and endothelial markers in primary tumors and classical epithelial CTCs (CTC-c). Scale in log10(rpm).
(B–D) Epithelial and mesenchymal genes differentially expressed in CTCs versus tumors.
Boxplot of epithelial genes that are (B) downregulated or mesenchymal genes that are (C) upregulated or (D) downregulated in CTCs (red) versus tumors (blue).
Bar represents median, and boxplot represents quartiles; scale in log10(rpm).
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expression and 774 genes with reduced expression (Table S1).
Gene Ontology (GO) analysis of CTC-enriched genes (Table
S2) indicated enrichment for signatures associated with
cellular interactions with environmental signals (GO:0045785,
positive regulation of cell adhesion), cell shape and structure
(GO:0030036, actin cytoskeleton organization), and transcrip-
tional states (GO:0045449, regulation of transcription). Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway analysis
(Table S3) similarly showed enrichment for focal adhesion (odds
ratio [OR] 2.7, q-value 6.7 3 104) and regulation of actin cyto-
skeleton (OR 2.4, q-value 0.005). Notably, of the KEGG signaling
pathways annotated, the mitogen-activated protein kinase
(MAPK) pathway was most highly enriched (OR 2.2, q-value
0.006); MAPK signaling is already activated in the KrasG12D-
driven primary tumor. However, while MSigDB Kras dependency
signatures were enriched in primary tumors compared with
CTCs, the latter had increased expression of Braf, Mras, and
Rras2, pointing to alternative paths to further activate MAPK in
CTCs. This finding is consistent with another study that identified
the MAPK pathway as being the most highly enriched in pancre-
atic CTCswithmicroarray-basedmethodologies (Carvalho et al.,
2013).
While single cells within the CTC cluster exhibited the charac-
teristic features of tumor cells, defining the identity of the
nonclassical CTC clusters, CTC-plt and CTC-pro, required
additional analyses. Compared with CTC-c, single cells within
the CTC-plt cluster were highly enriched for wound healing as
well as platelet and megakaryocyte expression profiles (Table
S4). While this suggests that these cells are either circulating
megakaryocytes/giant platelets or CTCs covered with adherent
platelets, tumor cell-specific lineage tagging supports the iden-
tification of CTC-plt cells as being of tumor origin. Eighteen
EGFP lineage-tagged single CTCs from two KPC-mT/mG
mice were subjected to single-cell RNA-seq: a total of nine
CTCs from the two mice (seven out of seven CTCs from
GMP1 and 2 out of 11 from GMP2) were included within
CTC-plt using unsupervised hierarchical clustering (Figure S2).
Thus, the CTC-plt cluster includes CTCs that exhibit strong
platelet markers, most likely derived from transcripts encoded
by adherent platelets. Interestingly, CTC-plt cells maintained
their distinct segregation from CTC-c, even after digital removal
of all annotated platelet transcripts (Figure S4). Thus, the adher-
ence of abundant platelets may modulate the intrinsic CTC
expression profile, as recently suggested by in vitro modeling
experiments (Labelle et al., 2011).
The CTC-pro cluster was most similar to both the NB508
pancreatic cancer cell line and MEFs, and it was enriched for
the cellular proliferation marker Mki67 when compared to CTC-
c. Multiple lineages are likely to have contributed to this complex
grouping; nine CTCs from the two KPC-mT/mG mice described
above clustered with CTC-pro (Figure S2), characterized by
abundant expression of Mki67 and an annotated cell-cycle
signature (Whitfield et al., 2002) (Figure S5). One single cell within
the CTC-pro cluster was derived from the pancreatic cancer cell
line NB508, while another (MP3-2) had high keratin/high E-cad-
herin expression characteristic of classical CTCs (Figure S3).
Another subcluster contained immune and dendritic cells, iden-
tified by their expression of antigen processing and presentation1910 Cell Reports 8, 1905–1918, September 25, 2014 ª2014 The Augenes (Table S5). Taken together, the CTC-pro cluster appears
to represent a grouping of highly proliferative cells, of which a
subset is tumor-derived CTCs.
Together, unbiased isolation and RNA-seq evaluation of single
pancreatic CTCs indicate that over half of these are nonviable
with RNA at various stages of degradation. Among the remaining
viable CTCs, threemajor classes are distinguishable by unsuper-
vised clustering: the classical subset (CTC-c) accounts for 55%,
with a second platelet-adherent group (CTC-plt; 32%) and a
third heterogeneous cluster marked by proliferative signatures
(CTC-pro; 13%). Given their most clearly defined tumor-derived
characteristics, we selected the CTC-c cluster for detailed anal-
ysis of metastasis-associated pathways.
Pancreatic CTCs Coexpress Epithelial, Mesenchymal,
and Stem Cell Markers
The relevance of EMT to early metastasis in pancreatic cancer
has been supported by lineage tracing studies in the KPCmouse
(Rhim et al., 2012). We recently reported a distribution of epithe-
lial and mesenchymal markers within individual CTCs in human
breast cancer, reflecting both tumor histology and response or
resistance to diverse therapies (Yu et al., 2013). To directly test
for EMT in the mouse pancreatic classical CTCs, we used estab-
lished epithelial (E) and mesenchymal (M) markers (Kalluri and
Weinberg, 2009) to evaluate each cell within theCTC cluster (Fig-
ure S6). Compared with the primary tumor, CTC-c cells demon-
strated clear loss of the epithelial markers E-cadherin (Cdh1) and
Muc1 (Figure 3B), whereas mesenchymal transcripts were
mixed, with some showing increased expression (Cdh11, Vim)
and others with reduced levels (S100a4, Itga5, Sdc1) (Figures
3C and 3D). Notably, even themesenchymal genes that were up-
regulated in CTCs showed a high degree of heterogeneous
expression across single cells (Figure S6). In contrast, loss of
E-cadherin (Cdh1) was nearly universal across all classical
CTCs, suggesting that pancreatic CTCs indeed lose some of
their epithelial characteristics.
CTCs are also likely to be enriched for metastatic precursors
capable of initiating metastatic tumor deposits. The relationship
between such precursor cells and cancer stem cells is uncertain,
as is the relevance of established stem cell markers in identifying
these cells. We evaluated putative pancreatic cancer stem cell
genes (Rasheed and Matsui, 2012; Rasheed et al., 2010) in the
single-cell RNA-seq reads (Figures 4A and S6). Among all candi-
date markers tested (Aldh1a1, Aldh1a2, Prom1/Cd133, Cd44,
Met, EpCAM), only Aldh1a1 and Aldh1a2 were enriched in
CTCs. Classical CTCs expressed predominantly the Aldh1a2
isoform, while Aldh1a1 was expressed in a variety of cell types
(Figure S6). Within single CTCs, there was no correlation be-
tween expression of Aldh1 isoforms and either enrichment for
the mesenchymal genes (Cdh11, Vim) or loss of epithelial genes
(Cdh1, Muc1), suggesting that stem cell and EMT markers are
not intrinsically linked in CTCs. Analysis of primary pancreatic tu-
mors forAldh1a2 using RNA in situ hybridization (RNA-ISH) iden-
tified rare epithelial tumor cells expressing this stem cell marker,
but the majority of expression was present within the cancer
associated stromal cells (Figure 4B), consistent with immunohis-
tochemistry for ALDH protein in human PDAC (Rasheed et al.,
2010).thors
Figure 4. CTC-Enriched Genes Found in Epithelial and Stromal Components of Primary Tumors
(A) Expression heatmap of stem cell genes and highly enriched CTC genes in primary tumors and CTC-c cells. Scale in log10(rpm).
(B–D) Expression boxplot (left) analysis of (B) Aldh1a2 stem cell and CTC highly enriched genes (C) Klf4 and (D) Igfbp5 genes with RNA-ISH of primary tumors
(right). Bar =median, box plot = quartiles, scale in log10(rpm). RNA-ISH color key shown (CK =Krt8+18). Circles indicate a subpopulation of keratin-positive tumor
cells with Aldh1a2marker, and arrowheads identify dual-positive cells at the epithelial-stromal interface (E, epithelial; S, stromal) with DAPI nuclear stain (blue).
Low-magnification fluorescent images taken at 1003magnification (scale bar represents 100 mm) and high magnification at 4003 (scale bar represents 20 mm).
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Classical CTCs Share Expression of Stromal
Enriched Genes
Besides the evident diversity of CTCs, we searched for shared
transcripts that might provide further insight into their cell of
origin within the primary tumor and the mechanisms by which
they invade and survive within the bloodstream and ultimately
identify potential CTC-specific therapeutic targets. We selected
rigorous criteria to identify the most highly enriched CTC-c
transcripts (RP score < 300), expressed at very high levels
(>100 rpm) in R90% of all classical CTCs. Three genes met
these criteria: Kruppel-like factor 4 (Klf4), one of the key stem
cell (iPS) reprogramming factors (Takahashi and Yamanaka,
2006), which has been implicated in pancreatic cancer develop-
ment (Brembeck andRustgi, 2000; Prasad et al., 2005;Wei et al.,
2010); insulin-like growth factor binding protein 5 (Igfbp5), an
extracellular growth factor binding protein expressed in human
PDAC reported to have both pro- and antiproliferative properties
(Johnson et al., 2006; Johnson and Haun, 2009); and decorin
(Dcn), a extracellular matrix proteoglycan expressed in tumor
stroma across a variety of different cancers (Adany et al.,
1990; Bostro¨m et al., 2013; Henke et al., 2012; Hunzelmann
et al., 1995; Iozzo and Cohen, 1994; Mu et al., 2013; Nash
et al., 2002). We utilized RNA-ISH in primary tumor specimens
to identify the potential colocalization of these three highly en-
riched CTC genes. In contrast to Aldh1a2, Klf4 is expressed in
epithelial components of the primary tumor (Figure 4C). Igfbp5
is of particular interest, in that it is expressed focally at the tumor
epithelial-stromal interface (Figure 4D). This geographic area
may be enriched for cancer cells undergoing EMT, contributing
to the mixed epithelial/stromal transcriptional programs evident
by RNA-seq of single CTCs.
In addition to highly expressing Dcn, CTCs consistently had
high levels of multiple ECM gene transcripts. GO analysis of all
CTC-enriched genes (Table S2) identified 32 proteinaceous
ECM genes (GO:0005578, OR 2.4, q-value 4.8 3 103). These
genes are normally expressed in reactive stromal cells, rather
than in epithelial cancer cells, and while recent studies have
highlighted the importance of the stroma in supporting pancre-
atic cancer pathogenesis and metastasis (Feig et al., 2012;
Neesse et al., 2011, 2013; Olive et al., 2009; Provenzano et al.,
2012), the expression of these stroma-associated ECM genes
within tumor cells in circulation was unexpected. Using RP differ-
ential expression analysis, we compared CTCs with purified
EGFP-tagged primary tumor single cells (TuGMP3) and bulk tu-
mor samples (tumor cells admixed with reactive stromal cells).
Six proteinaceous ECM genes were highly expressed by CTCs
and by stromal component, but not by epithelial cells within pri-
mary tumors: Dcn, Sparc, Ccdc80, Col1a2, Col3a1, and Timp2
(Figure 5A). RNA-ISH analysis of both Dcn and Sparc confirmed
diffuse expression in stromal elements of mouse primary tumors,
with rare areas where these transcripts are colocalized with ker-
atin-expressing cells at the epithelial-stromal border (Figure 5B).
SPARC is a well-known ECM protein gene found in stroma of
human primary PDAC (Infante et al., 2007; Neuzillet et al.,
2013; Sato et al., 2003). Indeed, RNA-ISH analysis of 198 primary
human PDACs demonstrates abundant stromal cell expression
of SPARC transcripts in 99% of cases, with up to a third of tu-
mors with rare epithelial cells expressing this ECM gene product1912 Cell Reports 8, 1905–1918, September 25, 2014 ª2014 The Au(Figure 5C). Consistent with these observations, RNA-seq of
EGFP-tagged single primary tumor cells (Figure 5A) identified
only 1 of 20 cells (5%) with coexpression of high levels
(>100 rpm) of Sparc and Krt19. In summary, abundant expres-
sion of ECM genes is a common feature of all keratin-rich clas-
sical CTCs. This is in marked contrast to the primary tumor,
where these gene products are secreted by supporting stromal
cells and not by the epithelial cancer cells. However, rare cells
at the epithelial-stromal interface of primary tumors do appear
to express both keratins and ECM genes, consistent with the
pattern observed in CTCs themselves.
Human CTCs Express Diverse Proteinaceous
ECM Genes
To confirm the expression of proteinaceous ECM genes by
human cancer cells circulating in the bloodstream, we isolated
single CTCs from patients with pancreatic (n = 7), breast (n =
29), and prostate (n = 77) cancers and subjected these to sin-
gle-cell RNA-seq. Six ECM protein genes were highly expressed
in human CTCs (>100 rpm in >15% of all CTC samples) (Fig-
ure 5D; Table S6). Notably, three genes (SPARC, MGP,
SPON2) are ECM glycoproteins, defined as part of the core ma-
trisome (Naba et al., 2012). The core matrisome protein SPARC
was particularly enriched in pancreatic CTCs being expressed at
high levels (>100 rpm) in 100% of pancreatic CTCs compared to
31%of breast and 9%of prostate CTCs. The notable differences
in ECM protein gene expression across human epithelial CTCs
suggest microenvironment tissue specificity as well as probable
redundancies in ECM protein signaling. Together, the consistent
expression of ECM gene family members in human CTCs sug-
gests that their upregulation may contribute either to the gener-
ation of CTCs from primary tumors or to the survival of cancer
cells deprived of microenvironmental signals as they circulate
in the bloodstream.
ECM Protein Gene SPARC Enhances Pancreatic Cancer
Metastatic Potential
In order to define the functional consequences of SPARC
expression in pancreatic cancer cells, we screened a panel of
patient-derived, low-passage PDAC cell lines for expression.
Two human PDAC cell lines with relatively high SPARC expres-
sion were identified (PDAC2 and PDAC3), making it possible to
test the consequences of small hairpin RNA (shRNA)-mediated
knockdown (Figures 6A, 6B, and S7). Suppression of endoge-
nous SPARC expression in both PDAC2 and PDAC3 cell lines
using two independent shRNA constructs did not affect prolifer-
ation in 2D cultures or anchorage-independent tumor sphere for-
mation (Figures 6C, 6D, and S7). However, SPARC knockdown
by both shRNAs significantly reduced pancreatic cancer cell
migration in wound scratch assays and their invasive properties,
as measured by in vitro Boyden assays (Figures 6E–6G and S7).
Tail vein injection of SPARC-suppressed PDAC3 cells using both
shRNA constructs generated significantly fewer lungmetastases
than cells expressing nontargeting hairpin (shNT) controls (Fig-
ure 6H). Metastases generated from orthotopic pancreatic xeno-
grafts were also significantly reduced for SPARC-suppressed
PDAC3 cells, as measured by luciferase imaging and normalized
for primary tumor size (Figure 6I). Thus, SPARC expression bythors
Figure 5. Human and Mouse CTCs across Different Epithelial Cancer Express High Levels of ECM Protein Genes
(A) Expression heatmap of mouse single primary tumor cells, bulk tumor, and CTCs for ECM protein genes. Scale in log10(rpm).
(B) RNA-ISH of ECM protein genes Dcn and Sparc with CK (Krt8+18) in mouse primary PDAC tumors.
(C) RNA-ISH of SPARC with CK (KRT7,8,18,+19) in human primary PDAC tumors. Arrowheads identify dual-positive cells at the epithelial-stromal interface
(E, epithelial; S, stromal) with DAPI nuclear stain (blue). Images taken at 4003 magnification (scale bar represents 20 mm).
(D) Expression boxplot of highly expressed ECMgenes in human PDAC, breast (BR), and prostate (PR) CTCs. Bar, median; boxplot, quartiles; scale in log10(rpm).
Holm-adjusted p value < 0.05 (*), 0.01 (**), 0.001 (***).
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Figure 6. SPARC Expression in Human PDAC Enhances Invasion and Metastasis
(A–C) Relative SPARC expression in (A) patient-derived human PDAC cell lines and in (B) PDAC3 cell line with shRNA against SPARC and nontarget (NT). Error
bars represent range. (C) Proliferation of PDAC3 cell lines determined by MTT.
(D) Tumor spheres in PDAC3 shNT versus shSPARC counted per 43 field (error bars represent SD).
(E) Boyden migration chamber assay stained with crystal violet and imaged.
(F) Scratch assay of shSPARC and shNT cell lines at 24 hr.
(G) Invasion of shSPARC and shNT cell lines quantitated by number of nuclei/203 field. p value < 0.01 (**), 0.001 (***), 0.0001 (****). Error bars represent SD.
(H) Percentage of detectable lungmetastases by in vivo luciferase imaging after 3 weeks after tail vein inoculation of PDAC3 cell lines. Fisher’s exact test p value is
shown.
(I) Normalized metastasis burden in mice with orthotopic pancreatic tumors from PDAC3 cell lines. Error bars represent SD (*p < 0.05).
1914 Cell Reports 8, 1905–1918, September 25, 2014 ª2014 The Authors
Figure 7. Summary Model of the Role of Pancreatic CTCs in the
Metastatic Cascade
Shown are the heterogeneous subsets of pancreatic CTCs with a focus on the
most prominent classical CTC group, which are enriched for coexpression of
epithelial (keratin) and stromal (Sparc) genes.pancreatic cancer cells appears to selectively enhance their
invasive and migratory properties to augment metastatic viru-
lence. The high levels of SPARC expression evident in virtually
all pancreatic CTCs thus raises the possibility that it contributes
significantly to the metastatic spread of pancreatic cancer.DISCUSSION
We present a detailed analysis of CTC composition and diversity
in pancreatic cancer, using single-cell RNA-seq. We achieved
high-quality transcriptomes in 93 single mouse pancreatic
CTCs, which were compared with bulk and single-cell prepara-
tions from matched primary tumors and from an immortalized
cell line established from the same mouse pancreatic tumor
model. The use of the KPC mouse model made it possible to
compare simultaneously isolated primary tumor specimens
and CTCs, and it allowed measurements of CTC heterogeneity
across multiple mice sharing the same Kras/Trp53 genetic
drivers. The large number of isolated CTCs and the high quality
of the isolated RNA from these cells reflect the application of
the CTC-iChip technology, which effectively depletes normal
blood components, enriching for CTCs that are untagged and
accessible for single-cell manipulation. Finally, the purification
of CTCs irrespective of their cell-surface epitopes avoids any
bias associated with their purification based on expression of
common epithelial markers such as EpCAM.
Together, our observations include the following. (1) CTC
expression profiles cluster into three classes, including a major
‘‘classical CTC’’ group, and others that are defined by platelet-
derived markers or proliferative signatures. (2) Common features
shared by virtually all classical CTCs include expression of both
epithelial and mesenchymal markers, the stem cell-associated
gene Aldh1a2, and three highly expressed transcripts, Klf4,
Igfbp5, and Dcn. The specific localization of Igfbp5-expressing
cells at the epithelial-stromal boundary within primary tumors
may point to a region that contributes significantly to CTC gener-Cell Reation. (3) The most highly enriched CTC-specific transcripts
shared by almost all classical CTCs encode extracellular matrix
proteins, such as Sparc. (4) Aberrant expression in CTCs of this
ECM gene product, which is normally abundant in the tumor
stromal compartment, is observed in both mouse and human
pancreatic CTCs, and its knockdown attenuates cancer cell
migration and invasion in reconstituted systems. (Figure 7)
Compared with our previous RNA-seq of partially purified,
bulk CTC populations, which required digital subtraction of
leukocyte-derived reads (Yu et al., 2012, 2013), the single-cell
analysis reported here provides considerably more depth of tu-
mor cell-specific transcript reads, and it allows measurements
of CTC heterogeneity. The feasibility of single-cell RNA-seq
applied to CTCs has been reported for small numbers of immu-
noselected melanoma and prostate CTCs (Cann et al., 2012;
Ramsko¨ld et al., 2012), and our work extends these studies by
providing a comprehensive landscape of mouse pancreatic
CTCs, whose gene expression profile is directly compared to
matched primary tumor cells. Since KPCmice primarily produce
disseminated micrometastatic foci, we were unable to directly
compare the expression profile of CTCs with that of metastatic
lesions. The shared genetic drivers in the KPC mouse model
enabled the collection and analysis of sufficient numbers of sin-
gle CTCs across different animals, yet we note significant ani-
mal-specific clustering in RNA-seq data. Thus, in addition to
the initiating mutations, somatically acquired genetic and epige-
netic changes may distinguish CTCs derived from different tu-
mors. Multiple mouse tumors contributed to each of the three
distinct clusters of CTCs. Despite their atypical expression
pattern, the identification of platelet-associated and proliferative
CTC subsets as being tumor-derived is established by their in-
clusion of lineage-tagged tumor cells. The more characteristic
expression pattern exhibited by the classical CTC cluster
enabled detailed comparison with primary tumor cells, thereby
providing further insight into the origin and properties of CTCs.
Mouse pancreatic classical CTCs uniformly lose expression of
the epithelial marker E-cadherin (Cdh1), a key feature of epithe-
lial-to-mesenchymal transition. However, the cells do not lose
expression of other epithelial markers, such as cytokeratins,
nor is there a consistent increase in classical mesenchymal
markers such as vimentin. As such, most classical CTCs appear
arrested in a biphenotypic state. Despite their expression of cy-
tokeratins, which are present in the epithelial components of the
primary tumor, most other highly expressedmarkers in CTCs are
sharedwith the stromal component of the primary tumor. Among
these stromal genes is Aldh1a2, a putative pancreatic cancer
stem cell marker (Rasheed and Matsui, 2012; Rasheed et al.,
2010). A provocative observation relating to the shared epithelial
andmesenchymal state of classical CTCs is their virtually univer-
sal (93%) expression of Igfbp5, which is uniquely expressed in a
small subpopulation of cells at the epithelial/stromal interface
within primary tumors. This raises the possibility that this critical
location within the primary tumor generates a disproportionate
fraction of viable CTCs. The postulated role of human IGFBP5
in metastasis (Hao et al., 2004) as well as in pancreatic malig-
nancy (Johnson et al., 2006; Johnson and Haun, 2009) makes
its unique expression pattern in both tumors and CTCs particu-
larly noteworthy.ports 8, 1905–1918, September 25, 2014 ª2014 The Authors 1915
The most unexpected observation from our single-CTC RNA-
seq study is the high abundance of ECM transcripts in the vast
majority of classical CTCs. The coexpression of pancreatic
cancer-enriched cytokeratins (Krt7 and Krt19) in single cells ex-
pressing these ECM gene products excludes the possibility
that these represent circulating tumor-derived fibroblasts. Inter-
estingly, prior evaluation of matched primary and metastatic
breast tumors identified the most prevalent gene expression
difference as enrichment for ECM molecules in the metastases,
comprising some 18% of differentially expressed genes (Wei-
gelt et al., 2005). While this has been interpreted as reflecting
differences in the local environment of the metastatic site, our
data suggest that ECM proteins are highly expressed by
CTCs themselves. By analogy with the classical ‘‘seed versus
soil’’ debate (Fidler, 2003), CTCs may in fact be seeds carrying
some of their own soil. These findings are also consistent with
recent work highlighting the importance of tumor stromal
signaling in priming cancer cells to metastasize (Zhang et al.,
2013).
Consistent with the aberrant expression of SPARC in some
pancreatic cancer cells, a subset of patient-derived tumor cell
lines also coexpress it along with epithelial cytokeratins. The
reduction in cell migration and metastatic potential exhibited
by these pancreatic cell lines following SPARC knockdown
suggests that it may contribute to CTC-mediated metastasis,
consistent with prior work in breast cancer models (Minn
et al., 2005). However, Sparc null pancreatic mouse tumors
demonstrate some effects on collagen maturation but do not
show suppressed metastasis (Neesse et al., 2014). Similar find-
ings have been reported in prostate and breast Sparc null
mouse cancer models (Wong et al., 2008). Thus, Sparc expres-
sion may contribute to metastasis, but inherent redundancies in
ECM protein expression may mitigate this effect. Nonetheless,
considerable effort has been directed to targeting the pancre-
atic cancer stroma as a means of improving delivery of chemo-
therapeutics as well as stripping tumor cells of their supportive
microenvironment (Neesse et al., 2011; Olive et al., 2009; Pro-
venzano et al., 2012; Rasheed et al., 2012). Our finding that
these gene products are also expressed by CTCs themselves
suggests a remarkable level of cellular plasticity. To the extent
that invasive properties of CTCs are mediated in part by
expression of such ECM proteins, it also raises the possibility
of targeting cancer cells in the blood.
The ability to dissect critical components of the metastatic
process at the single-cell level depends upon critical techno-
logical developments that have only recently become available,
namely the efficient isolation of extraordinarily rare CTCs in
solution without the bias of tumor antigen selection combined
with the ability to perform high-fidelity single-cell RNA-seq.
These approaches now allow CTC analyses to extend from
matching them to known tumor-defining markers to interro-
gating them for unique properties that in fact distinguish them
from primary tumor cells. Identifying such CTC-specific gene
expression patterns may provide additional insight into mecha-
nisms that underlie their ability to survive in the bloodstream
and generate distant metastases, which are critical to the
ultimate goal of preventing the spread of cancer to distant
organs.1916 Cell Reports 8, 1905–1918, September 25, 2014 ª2014 The AuEXPERIMENTAL PROCEDURES
Mice and Cell Lines
Mice with pancreatic cancer used in these experiments express Cre driven by
Pdx1, LSL-KrasG12D, and Trp53lox/+ or Trp53lox/lox as previously described
(Bardeesy et al., 2006). EGFP pancreatic lineage-tagged KPC mice were
generated by breeding the mT/mG mouse [Jackson Laboratory; Gt(ROSA)
26Sortm4(ACTB-tdTomato,-EGFP)Luo/J] into the breeder pairs used for
KPCmouse generation. Normal FVBmice were purchased from Jackson Lab-
oratory. All mice care and procedures were done under Massachusetts Gen-
eral Hospital (MGH) Subcommittee on Research Animal Care-approved
protocols.
Human CTCs and Cell Lines
Human blood for CTC analysis was obtained after consent was obtained on
an existing Dana-Farber/Harvard Cancer Center institutional review board
(IRB)-approved protocol (05-300) at the Massachusetts General Hospital. A
maximum of 20 ml of blood was obtained from patients at any given blood
draw in two 10 ml EDTA tubes, and approximately 8–10 ml of blood was pro-
cessed per patient. Newly derived pancreatic cancer cell lines were generated
from metastatic ascites fluid from patients receiving diagnostic or therapeutic
paracentesis under MGH IRB protocol 2011P001236. Cell lines were subcul-
tured until a pure cell line was obtained. All cell lines studied had KRAS muta-
tion genotyping to confirm cancer origins, and both PDAC2 and PDAC3 were
both found to have KRAS G12V point mutations. Cell lines were grown in
standard culture conditions using Dulbecco’s modified Eagle’s medium,
high glucose + 10% fetal bovine serum + 1% penicillin/streptomycin (Gibco/
Life Technologies).
CTC Enrichment Technology
Given the desire for an unbiased enrichment system, the previously presented
negative depletion technology was selected for this application. Before
running blood, mouse and human blood were analyzed by a cell blood count
machine to determine total WBC count. For mouse CTC samples, a rat anti-
mouse CD45 antibody (BAM114, R&D Systems) was preconjugated to Dyna-
beadsMyOne Strepavidin T1 (Life Technologies, 65602). Beads were added at
a ratio of 125 beads/WBC, mixed, and incubated for 40 min at room temper-
ature. Human CTC samples utilized a primary and secondary immunolabeling
approach. Biotinylated primary antibodies against anti-human CD45 antibody
(clone 2D1, R&D Systems, BAM1430) and anti-human CD66b antibody (Abd
Serotec, 80H3) were spiked into whole blood at 100 fg/WBC and 37.5 fg/
WBC, respectively, and incubated rocking at room temperature for 20 min.
DynabeadsMyOne Strepavidin T1 (Life Technologies, 65602) were then added
and incubated rocking at room temperature for an additional 20 min.
Single-Cell Micromanipulation, Amplification, and Sequencing
After whole-blood CTC-iChip processing, the product containing enriched
cells was collected in a 35 mm petri dish and viewed using a Nikon Eclipse
Ti invertedmicroscope. Cells of interest were identified based on intact cellular
morphology and lack of labeling with anti-CD45magnetic beads. These target
cells were individually micromanipulated with a 10 mm transfer tip on an
Eppendorf TransferMan NK 2 micromanipulator and ejected into PCR tubes
containing RNA protective lysis buffer and immediately flash frozen in liquid ni-
trogen. Single cells were amplified with a modified protocol (Tang et al., 2010)
and sequenced on the ABI 5500XL system.
RNA In Situ Hybridization
RNA-ISH was performed according to the Affymetrix ViewRNA ISH Tissue-2
Plex Assay. Fluorescent images were taken in using a Nikon 90i microscope.
See Supplemental Experimental Procedures for details.
ACCESSION NUMBERS
Pancreatic and breast sequencing data have been deposited to the NCBI
Gene Expression Omnibus with the accession numbers GSE51372,
GSE60407, and GSE51827.thors
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seven figures, and six tables and can be found with this article online at
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